BR112013025934A2 - tratamento de infecção pelo vírus da hepatite c com alisporivir - Google Patents

tratamento de infecção pelo vírus da hepatite c com alisporivir

Info

Publication number
BR112013025934A2
BR112013025934A2 BR112013025934A BR112013025934A BR112013025934A2 BR 112013025934 A2 BR112013025934 A2 BR 112013025934A2 BR 112013025934 A BR112013025934 A BR 112013025934A BR 112013025934 A BR112013025934 A BR 112013025934A BR 112013025934 A2 BR112013025934 A2 BR 112013025934A2
Authority
BR
Brazil
Prior art keywords
hepatitis
treatment
virus infection
alisporivir
relates
Prior art date
Application number
BR112013025934A
Other languages
English (en)
Inventor
Claudio Avila
Rafael Crabbé
Original Assignee
Debiopharm Int Sa
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025934(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm Int Sa, Novartis Ag filed Critical Debiopharm Int Sa
Publication of BR112013025934A2 publication Critical patent/BR112013025934A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "tratamento de infecção pelo vírus da hepatite c com alisporivir". a presente invenção refere-se à utilização de inibidores da ciclofilina no tratamento da infecção pelo vírus da hepatite c.
BR112013025934A 2011-04-13 2012-04-11 tratamento de infecção pelo vírus da hepatite c com alisporivir BR112013025934A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474946P 2011-04-13 2011-04-13
PCT/EP2012/056577 WO2012140082A1 (en) 2011-04-13 2012-04-11 Treatment of hepatitis c virus infection with alisporivir

Publications (1)

Publication Number Publication Date
BR112013025934A2 true BR112013025934A2 (pt) 2016-09-06

Family

ID=45937376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025934A BR112013025934A2 (pt) 2011-04-13 2012-04-11 tratamento de infecção pelo vírus da hepatite c com alisporivir

Country Status (18)

Country Link
US (2) US20150104415A1 (pt)
EP (1) EP2696883A1 (pt)
JP (1) JP2014510772A (pt)
KR (1) KR20140011379A (pt)
CN (1) CN103648516A (pt)
AR (1) AR085988A1 (pt)
AU (2) AU2012241859A1 (pt)
BR (1) BR112013025934A2 (pt)
CA (1) CA2832829A1 (pt)
CL (1) CL2013002914A1 (pt)
IL (1) IL228725A0 (pt)
MA (1) MA35029B1 (pt)
MX (1) MX2013011941A (pt)
RU (1) RU2013150344A (pt)
SG (2) SG193908A1 (pt)
TN (1) TN2013000397A1 (pt)
TW (1) TW201247217A (pt)
WO (1) WO2012140082A1 (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
MX2007003387A (es) 2004-10-01 2007-05-23 Debiopharm Sa Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infeccion por hepatitis c y composicion farmaceutica que comprende la [d-meala]3-[etval]4-ciclosporina.
RU2007128099A (ru) 2004-12-23 2009-01-27 Новартис АГ (CH) Композиции для лечения гепатита с
WO2008052722A2 (en) 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug

Also Published As

Publication number Publication date
MA35029B1 (fr) 2014-04-03
JP2014510772A (ja) 2014-05-01
TW201247217A (en) 2012-12-01
AU2016200061A1 (en) 2016-01-28
KR20140011379A (ko) 2014-01-28
US20150104415A1 (en) 2015-04-16
CA2832829A1 (en) 2012-10-18
EP2696883A1 (en) 2014-02-19
SG193908A1 (en) 2013-11-29
IL228725A0 (en) 2013-12-31
AU2012241859A1 (en) 2013-10-10
CL2013002914A1 (es) 2014-06-27
WO2012140082A1 (en) 2012-10-18
US20160235808A1 (en) 2016-08-18
AR085988A1 (es) 2013-11-13
CN103648516A (zh) 2014-03-19
SG10201602184TA (en) 2016-04-28
RU2013150344A (ru) 2015-05-20
TN2013000397A1 (en) 2015-01-20
MX2013011941A (es) 2014-05-28
NZ615539A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201691837A1 (ru) Противовирусные агенты против гепатита в
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
BR112015000561A2 (pt) inibidores de irak e usos dos mesmos
BR112015014555A2 (pt) composições pesticidas e processos relacionados a isso
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
NZ702744A (en) D-amino acid compounds for liver disease
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
NZ702458A (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
BR112013022391A2 (pt) composições, métodos de tratamento e diagnóstico para o tratamento de esteatose hepática apenas ou em combinação com uma infecção pelo vírus da hepatite c e uso dessas composições
BR112014011351A2 (pt) inibidores de acc e usos dos mesmos
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
ECSP14013312A (es) Composiciones para el tratamiento de vhc
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
IN2014CN03307A (pt)
RS53911B1 (en) TREATMENT IN HEPATITIS B VIRUS INFECTION ONLY OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND THE DISEASES OF THE LIVER
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112014013972A2 (pt) inibidores de hcv nssa
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]